Samira Pirzad

Samira Pirzad

Auto-generated profile, based on publicly available information

Samira Pirzad

Faculty of Medicine, Islamic Azad University, Tehran Medical Sciences Branch (IAUTMU), Tehran, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2025 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Open access
ASAzin Setayesh
Azin Setayesh
MKMehdi Karimi
Mehdi Karimi
MKMohammad Amin Karimi
Mohammad Amin Karimi
SPSamira Pirzad
Samira Pirzad
MHMahdis Heydari
Mahdis Heydari
BLBagher Larijani
Bagher Larijani
Probiotic and synbiotic supplementation has garnered attention for its potential to modulate metabolic parameters, including glycemic control, in individuals with prediabetes and type 2 diabetes mellitus (T2DM). This systematic review and dose-response meta-analysis aims to evaluate the effectiveness of these supplements on glycemic indices, synthesizing evidence from randomized controlled trials (RCTs) with grade-assessed methodologies. A comprehensive search of scientific databases was conducted from inception through January 2025 to identify RCTs assessing the effects of probiotic and synbiotic supplementation on glycemic indices, including fasting blood glucose (FBG), fasting insulin (FI), hemoglobin A1c (HbA1c), and homeostatic model assessment for insulin resistance (HOMA-IR). Eligible studies were screened; relevant data were extracted, and the quality of evidence was evaluated using the GRADE approach. Statistical analyses were performed using STATA to generate pooled results. The pooled analysis of 48 RCTs demonstrated that probiotics and synbiotics supplementation significantly decreased FBG (WMD: - 7.00 mg/dL), FI (WMD: - 1.72 µIU/mL), HbA1c levels (WMD: - 0.34%), and HOMA-IR (WMD: - 0.91), with a substantial heterogeneity across all outcomes (p < 0.001). Subgroup analyses indicated reductions in FBG, FI, HbA1c, and HOMA-IR across varying baseline characteristics, including glycemic levels, trial durations, and participant health status. Both probiotics and synbiotics were effective, with notable benefits for patients with T2DM, longer intervention durations, and higher baseline BMI. Meta-regression and dose-response analyses revealed no significant association between the duration of probiotic and synbiotic supplementation and changes in glycemic indices. Probiotic and synbiotic supplements significantly reduce FBG, FI, HbA1c, and HOMA-IR, leading to improvements in glycemic markers in individuals with prediabetes and T2DM. These supplements can be used as effective adjunctive strategies to enhance glycemic control, highlighting the promising role of gut microbiota modulation in diabetes management.

27 November 2024 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MKMehdi Karimi
Mehdi Karimi
SPSamira Pirzad
Samira Pirzad
NSNiyousha Shirsalimi
Niyousha Shirsalimi
MHMohammad Hossein Hosseini
Mohammad Hossein Hosseini
PEPouya Ebrahimi
Pouya Ebrahimi
PRPegah Rashidian
Pegah Rashidian
Background: The incidence of diabetes mellitus (DM) is increasing worldwide, and there is growing interest in the potential use of natural compounds as an alternative treatment for managing DM. Several research studies have investigated the impact of saffron consumption on managing and improving metabolic profiles in patients with DM, and they have shown promising results. Object: The study aims to systematically review and perform a meta-analysis to evaluate the potential effects of saffron and its extract on cardiometabolic indicators in diabetic and prediabetic overweight patients. Methods: We conducted a comprehensive systematic review and meta-analysis, searching PubMed, Scopus, Web of Science, Embase, and Google Scholar for all relevant studies published before April 20, 2024. We extracted weighted (WMD) or standardized (SMD) mean differences (before-after) and 95% confidence intervals (95%CI) of the outcomes and conducted meta-analyses using R. The study protocol was registered in PROSPERO (CRD42024538380). Results: Out of the studies screened, 15 RCTs were selected for inclusion in the systematic review and meta-analysis. These studies collectively involved 869 participants, 438 in the intervention group and 431 in the control group. Notably, our results showed that saffron supplementation led to significant changes in FBS (MD: − 8.75 mg/dL, 95% CI [− 14.75; − 2.76], P < 0.01), HbA1C (MD: − 0.34%, 95% CI [− 0.39; − 0.9], P < 0.01), TG (MD: − 13.28 mg/dL, 95% CI [− 22.82; − 3.75], P < 0.01), SBP (MD: − 5.33 mmHg, 95% CI [− 8.99–1.67], P = 0.04), DBP (MD: − 1.02 mmHg, 95% CI [− 3.91; 1.86], P = 0.03), AST (MD: − 1.32 IU/L, 95% CI [− 1.72, − 0.93], P < 0.01) levels in T2DM patients compared to placebo or no supplementation, indicating its potential as a therapeutic intervention. However, there was no significant effect on Insulin secretion (MD: − 0.15 µU/ml, 95% CI [− 2.1763; 1.8689], P = 0.88), HOMA (MD: − 0.35%, 95% CI [− 1.34;0.63], P = 0.48), TC (MD: − 4.86 mg/dL, 95% CI [− 9.81–0.09], P = 0.54), HDL (MD: 0.18 mg/dL, 95% CI [− 0.93; 1.29], P = 0.74), LDL (MD: − 1.77 mg/dL, 95% CI [− 5.99–2.45], P = 0.41), TNF-α (MD: − 0.34 pg/mL, 95% CI [− 0.99–0.30], P = 0.29), creatinine (MD: 2.83 mg/dL, 95% CI [2.29, 3.37], P = 0.31) and BUN (MD: − 0.44 mg/dL, 95% CI [− 1.43, 0.55], P = 0.38). Conclusion: Saffron may improve specific CMI indices in overweight patients with diabetes or prediabetes, including significant reductions in FBS, HbA1C, TG, SBP, and AST. However, it did not significantly affect HDL, TC, LDL, insulin secretion, HOMA, DBP, TNF-α, ALT, Cr, or BUN. Further research with more trials and extended follow-up periods is needed to confirm and expand these findings.

12 July 2025 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
MKMehdi Karimi
Mehdi Karimi
NBNazgol Bahreini
Nazgol Bahreini
SPSamira Pirzad
Samira Pirzad
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
NSNiyusha Shirsalimi
Niyusha Shirsalimi
BLBagher Larijani
Bagher Larijani

15 May 2025 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
SPSamira Pirzad
Samira Pirzad
FHFarnaz Hooshmand
Farnaz Hooshmand
NSNiyousha Shirsalimi
Niyousha Shirsalimi
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
Coenzyme Q10 is a naturally occurring antioxidant that has been suggested to improve cardiovascular health. Studies examining the effects of Q10 on blood pressure (BP) and heart rate (HR) have found inconsistent results. This meta-analysis aims to clarify the effects of Q10 administration on BP and HR in adults. A comprehensive search of online databases was conducted until February 2025 to identify relevant randomized controlled trials (RCTs). Following screening, relevant data were extracted from the eligible studies. Statistical analyses were conducted using weighted mean differences (WMD) with 95 % confidence intervals (CI). Data analysis was performed using the "meta" package in R. The pooled analysis of 45 RCTs (48 effect sizes) showed that Q10 administration significantly reduced systolic BP (WMD: −3.44 mmHg; 95 %CI: [-5.13 to −1.55], p < 0.01), while no significant effect was observed on diastolic BP (WMD: −1.13 mmHg; 95 %CI: [-2.16 – 0.50], p = 0.23) and HR (WMD: −0.10 bpm; 95 %CI: [-2.09 – 1.89], p = 0.44). Subgroup analysis indicated that lower doses (8 weeks) resulted in greater systolic BP reductions. This meta-analysis indicates that CoQ10 supplementation may be an effective adjunctive therapy for reducing systolic blood pressure, especially at doses below 200 mg/day and with longer treatment durations. However, its impact on diastolic blood pressure and heart rate appears minimal. Given its favorable safety profile, CoQ10 could be considered as a supportive option in the management of hypertension, particularly for patients seeking non-pharmacological interventions or those with mild elevations in systolic BP.

3 November 2025 in Addiction & Health
Verified
Journal Article
Open access
MSMehrdad Sinaeinejad
Mehrdad Sinaeinejad
MKMehdi Karimi
Mehdi Karimi
MRMohsen Razavizadeh
Mohsen Razavizadeh
AAAbbas Arj
Abbas Arj
STSeyyed Hamed Tabatabaei
Seyyed Hamed Tabatabaei
MKMehdi Kashani
Mehdi Kashani
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is a common liver disorder associated with metabolic abnormalities. This study aimed to evaluate the effectiveness of N-acetylcysteine (NAC) in improving liver function and metabolic profile in patients with MASLD. Methods: In this randomized controlled trial (RCT), 69 patients with MASLD were randomly assigned to either the NAC group (600 mg, administered three times daily, n=34) or the placebo group (n=35) for eight weeks. The severity of hepatic steatosis, liver enzymes, and metabolic profile were measured at baseline and the final trial. Data were analyzed using SPSS. Findings: Following eight weeks of NAC administration in patients with MASLD, no significant changes were observed compared to the placebo in hepatic steatosis grade (P=0.215), serum aspartate aminotransferase (AST) (P=0.21), alanine transaminase (ALT) (P=0.28), malondialdehyde (MDA) (P=0.79), total antioxidant capacity (TAC) (P=0.56), triglycerides (P=0.15), total cholesterol (P=0.28), low-density lipoprotein cholesterol (P=0.32), and high-density lipoprotein cholesterol (P=0.16). However, NAC administration resulted in significant reductions in fasting blood glucose (FBG) (P=0.01), fasting insulin levels (P<0.001), homeostatic model assessment for insulin resistance (HOMA-IR) (P<0.001), and C-reactive protein (CRP) (P<0.001), along with a significant increase in total glutathione levels (P=0.003), compared to the placebo group. Conclusion: NAC administration in patients with MASLD does not significantly impact hepatic steatosis, liver enzymes, or lipid profiles; however, it improves oxidative, glycemic, and inflammatory markers. Therefore, NAC may be a beneficial adjunct therapy for managing metabolic parameters and reducing inflammation and oxidative stress in MASLD patients. Trial Registration: The trial was registered with the Iranian Registry of Clinical Trials (IRCT20201220049772N1) on February 20, 2021.

8 October 2025 in Journal of Dietary Supplements
Verified
Journal Article
Closed access
MKMehdi Karimi
Mehdi Karimi
SASara Alipour
Sara Alipour
SPSamira Pirzad
Samira Pirzad
SASajad Ahmadizad
Sajad Ahmadizad
MBMinoo Bassami
Minoo Bassami
OAOmid Asbaghi
Omid Asbaghi
Adiponectin and leptin are pivotal adipokines regulating metabolic homeostasis, with dysregulation linked to obesity, insulin resistance, and related metabolic disorders. Vitamin E, a potent antioxidant, has been proposed to modulate adipokine secretion, but existing studies report inconsistent findings. This systematic review and meta-analysis aimed to evaluate the impact of vitamin E oral supplementation on serum adiponectin and leptin levels in adults. Systematic searches were performed in major electronic databases up to August 2025 to identify eligible randomized controlled trials (RCTs). Extracted data were analyzed using STATA, and pooled effect estimates were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs). The pooled analysis of 10 RCTs (14 effect sizes) showed that vitamin E supplementation did not significantly alter serum adiponectin (WMD: 0.67 ng/mL; 95% CI: [-0.11 - 1.44]; p = 0.093) or leptin levels (WMD: -3.60 ng/mL; 95% CI: [-7.45 - 0.25]; p = 0.067). Subgroup analyses revealed that long-term supplementation (>12 wk) significantly increased adiponectin (WMD: 1.60 ng/mL; p = 0.039), particularly in patients with nonalcoholic fatty liver disease (NAFLD) (WMD: 4.28 ng/mL; p < 0.001). Additionally, vitamin E significantly reduced leptin levels in NAFLD patients (WMD: -5.45 ng/mL; p < 0.001). This meta-analysis found no significant overall effect of vitamin E on adiponectin and leptin levels; however, long-term supplementation appears beneficial, particularly in patients with NAFLD. Heterogeneity in study design, dosage, and duration highlights the need for further well-designed RCTs to clarify the metabolic and therapeutic roles of vitamin E.